Skip to main content
ACAD
NASDAQ Life Sciences

FDA Fast Tracks Acadia's Remlifanserin for Alzheimer's Psychosis; Phase 2 Data Due by October

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$25.69
Mkt Cap
$4.384B
52W Low
$19.69
52W High
$28.35
52W Position info
30% above low
Off High info
9.4% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

ACAD sits 30% above its 52-week low of $19.69.

Summary

The FDA granted Fast Track designation to remlifanserin for Alzheimer's disease psychosis, a condition with no approved therapies. This regulatory milestone accelerates development and review, and follows a positive EMA opinion for Daybue in June. Enrollment in the Phase 2 RADIANT trial is complete, with topline results now expected between September and October 2026—a concrete near-term catalyst. Phase 3 screening is already underway, signaling confidence in the program. The news adds a clear value driver to Acadia's pipeline beyond its commercial products.

At the time of this announcement, ACAD was trading at $25.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $19.69 to $28.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

ACAD - Latest Insights

ACAD
Nov 04, 2026, 6:16 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $21.95
Real-time Price: $21.20 info
Change: -$0.7512 (-3%) info
Market Cap: $3.66B info
ACAD
Nov 04, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.46
Real-time Price: $21.20 info
Change: -$0.260 (-1%) info
Market Cap: $3.66B info
ACAD
Oct 05, 2026, 2:23 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $20.07
Real-time Price: $21.20 info
Change: +$1.13 (+6%) info
Market Cap: $3.66B info
ACAD
Sep 28, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $20.53
Real-time Price: $21.20 info
Change: +$0.670 (+3%) info
Market Cap: $3.66B info
ACAD
Sep 28, 2026, 7:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $20.65
Real-time Price: $21.20 info
Change: +$0.550 (+3%) info
Market Cap: $3.66B info